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Background: Serum total cholesterol (TC) and LDL cholesterol (LDL-C) have been used as major laboratory
measures in clinical practice to assess cardiovascular risk in the general population and disease management
as well as prognosis in patients. However, some studies have also reported the use of non-HDL cholesterol
(non-HDL-C). As non-HDL-C can be calculated by subtracting HDL-C from TC, both of which do not require fasting
blood sample in contrast to LDL-C which requires fasting blood sample, we aimed to compare non-HDL-C with
LDL-C as a predictor of myocardial infarction (MI).
Methods: This hospital based cross sectional study was undertaken among 51 cases of MI and equal number of
controls. MI was diagnosed based on the clinical history, ECG changes and biochemical parameters. 5 mL of fasting
blood sample was collected from each research participant for the analysis of lipid profile. Non-HDL-C was
calculated by using the equation; Non-HDL-C = TC – HDL-C. Statistical analysis was performed using SPSS 14.0.
Results: 42 MI cases were dyslipidemic in contrast to 20 dyslipidemic subjects under control group. The differences
in the median values of each lipid parameter were statistically significant between MI cases and controls. The lipid
risk factors most strongly associated with MI were HDL-C (OR 5.85, 95% CI 2.41-14.23, P value = 0.000) followed by
non-HDL-C (OR 3.77, 95% CI 1.64-8.66, P value = 0.002), LDL-C/HDL-C (OR 3.38, 95% CI 1.44-7.89, P value = 0.005),
TC/HDL-C (OR 2.93, 95% CI 1.36-7.56, P value = 0.026), LDL-C (OR 2.70, 95% CI 1.20-6.10, P value = 0.017), TC (OR 2.68,
95% CI 1.04-6.97, P value = 0.042) and Tg (OR 2.54, 95% CI 1.01-6.39, P value = 0.047). Area under the receiver
operating curve was greater for non-HDL-C than for LDL-C. Non-HDL-C was also found to be more sensitive and
specific than LDL-C for MI.
Conclusions: HDL-C and non-HDL-C are better discriminating parameters than LDL-C for MI. Thus, we can simply
perform test for HDL-C and non-HDL-C both of which do not require fasting blood sample rather than waiting for
fasting blood sample to measure LDL-C.
Keywords: Dyslipidemia, LDL cholesterol, Myocardial infarction, non-HDL cholesterol* Correspondence: manoj.sigdel@hotmail.com
1Department of Biochemistry, Manipal College of Medical Sciences, Pokhara,
Nepal
Full list of author information is available at the end of the article
© 2012 Sigdel et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Sigdel et al. BMC Research Notes 2012, 5:640 Page 2 of 5
http://www.biomedcentral.com/1756-0500/5/640Background
A dramatic increase in the incidence of myocardial in-
farction (MI) has been observed in many countries. It
has become one of the major causes of morbidity and
mortality in the middle aged and elderly population.
Generally, MI results from risk factors for atheroscler-
osis [1]. Dyslipidemia has been proven to be an import-
ant modifiable risk factor for MI [2]. Serum total
cholesterol (TC) and low density lipoprotein cholesterol
(LDL-C) have been used as major laboratory measures
in clinical practice to assess cardiovascular risk in the
general population and disease management as well as
prognosis in patients [3]. Recent studies, however, have
shown that non-high density lipoprotein cholesterol
(non-HDL-C) concentration is similar to or better than
LDL-C alone in the prediction of cardiovascular disease
(CVD) incidence and mortality [4-7]. Unlike LDL-C,
which can be incorrectly calculated in the presence
of postprandial hypertriglyceridemia, non-HDL-C is
reliable when measured in the non-fasting state [8].
Non-HDL-C can be calculated by subtracting HDL-C
from TC both of which do not require fasting blood
sample. Therefore, we aimed to compare non-HDL-C
with LDL-C as a predictor of MI.
Methods
This is a cross-sectional study among 51 cases of MI ad-
mitted at Coronary care unit of Shahid Gangalal Na-
tional Heart Centre, Bansbari, Kathmandu from 25th
July to 24th Nov, 2010. MI was diagnosed based on the
clinical history, ECG changes and biochemical para-
meters. During the time of admission of the patient,
Troponin I was performed by Acon kit and CK-MB was
performed by an analyser from Dade Baring. Fasting
blood samples for lipid profile were collected on the
morning of second day of admission. Equal number of
age and sex matched healthy controls were chosen for
comparison. The control subjects were such chosen that
they did not have a history of CVD. Both patients and
controls were living in the same area during the time
period of the study. Lipid profile: TC, triglycerides (Tg)
and HDL-C were performed in the biochemistry labora-
tory of Tribhuvan University Teaching Hospital, Kath-
mandu, from fully automated biochemistry analyzer BT
2000 plus. Non-HDL-C was calculated as TC minus
HDL-C. LDL-C was calculated using Friedwald’s equa-
tion; LDL-C = TC – (HDL-C + Tg/5). LDL-C/HDL-C
and TC/HDL-C ratios were calculated mathematically.
Research proposal was approved by Institutional Review
Board, Institute of Medicine and written consent was
taken from all the participants. National Cholesterol
Education Programme Adult Treatment Panel III
(NCEP-ATPIII) guidelines was referred to define dyslipi-
demia [3]. According to NCEP-ATPIII guideline,hypercholesterolemia is defined as TC > 200 mg/dl,
LDL-C as >100 mg/dl, hypertriglyceridemia as Tg
>150 mg/dl and low HDL-C as <40 mg/dl. Dyslipidemia
was defined by the presence of one or more than one
abnormal serum lipid concentration. Non-HDL-C was
considered normal below 130 mg/dl. Statistical analysis
was performed using SPSS 14. Test for normality of data
was done by Shapiro-Wilk Test. As there was not nor-
mal distribution of data, medians were compared by
using Mann–Whitney U test and correlations among the
different lipid parameters were determined using Spear-
man’s rank correlation test. Sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value
(NPV) of each lipid parameters were calculated by using
chi-square test. The odds ratio (OR) (and the corre-
sponding confidence interval) of having MI was estimated
using Mantel-Haenszel common odds ratio. Receiver
Operating Characteristic (ROC) curve was constructed
and area under the curve (AUC) was obtained for lipid
parameters. All reported probability values (P-values)
were based on two-sided tests and P value <0.05 was con-
sidered statistically significant.
Results
Among the total of 51 MI diagnosed cases, 36 (70.6%)
were males and 15 (29.4%) were females. The mean age
of MI cases was 60.96 years; ranging from 30 years to
98 years. Dyslipidemia was found on 42 (82.35%) cases.
Out of four sub-sets of lipid profile, namely: TC, LDL-C,
HDL-C and Tg, nine cases were dyslipidemic by one
parameter, twenty cases by two parameters, nine cases
by three parameters, and four cases by all four para-
meters. Hypercholesterolaemia was found on 17
(33.34%), hypertriglyceridaemia on 18 (35.29%), and an
increase of LDL-C was found on 27 (57.44%) cases.
Decreased HDL-C level was found on 30 (58.82%) cases
(Table 1). However, only 20 (39.21%) of the controls
were found to be dyslipidemic by one or more para-
meters. For each lipid parameter, the differences in me-
dian lipid values were statistically significant between MI
cases and controls (Table 2). The lipid risk factors most
strongly associated with MI were HDL-C (OR 5.85, 95%
CI 2.41-14.23, P value = 0.000) followed by non-HDL-C
(OR 3.77, 95% CI 1.64-8.66, P value = 0.002), LDL-C/
HDL-C (OR 3.38, 95% CI 1.44-7.89, P value = 0.005),
TC/HDL-C (OR 2.93, 95% CI 1.36-7.56, P value = 0.026),
LDL-C (OR 2.70, 95% CI 1.20-6.10, P value = 0.017), TC
(OR 2.68, 95% CI 1.04-6.97, P value = 0.042) and Tg (OR
2.54, 95% CI 1.01-6.39, P value = 0.047). These findings
were confirmed in the ROC analysis, which also sug-
gested a strong association of these variables with MI.
AUC was highest for HDL-C (0.834) followed by TC/
HDL-C (0.789), LDL-C/ HDL-C (0.748), non-HDL-C
(0.734), TC (0.709), LDL-C (0.708), and Tg (0.638). The
Table 1 Lipid profile status of MI cases
Total cholesterol Triglycerides HDL-cholesterol LDL-cholesterol Non-HDL cholesterol
Normal High Normal High Normal Low Normal High Normal High
34 17 33 18 21 30 24 27 30 21
(66.66%) (33.34%) (64.71%) (35.29%) (41.18%) (58.82%) (42.56%) (57.44%) (58.52%) (41.17%)
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off points suggested by NCEP ATP III is given in Table 3.
Non-HDL-C was significantly correlated with TC (r =
0.991, P < 0.0001), LDL-C (r = 0.960, P < 0.0001), TC/
HDL-C (r = 0.927, P < 0.0001), LDL-C/HDL-C (r = 0.915,
P < 0.0001), HDL (r = −0.445, P < .0001) and Tg (r =
0.410, P < 0.0001). However, the correlation of LDL was
insignificant with Tg (r = 0.152, P > 0.05).
Discussion
This is probably the first case–control study in our part
of the world aiming at identifying the importance of
non-HDL-C in patients with MI. In our study, we identi-
fied HDL-C as the lipid parameter most strongly asso-
ciated with MI followed by non-HDL-C. The association
between low levels of HDL-C and an increased risk for
CVD has been well established through epidemiological
and clinical studies [9]. In a prospective study conducted
among 1,799 Finnish men, it was shown that serum
HDL-C of less than 42 mg/dl was associated with a 3.3-
fold risk of MI. Adjustments for body mass index (BMI),
history of diabetes mellitus (DM) (yes versus no), serum
Tg and LDL-C concentration did not influence thisTable 2 Comparison of lipid status between MI cases and
controls (median, 25th-75th percentile)
Parameters MI cases Control P value
TC (mg/dl) 173.70 139.32 0.000
142.82-212.30 119.97-174.15
Tg (mg/dl) 131.55 113.94 0.016
96.47-192.94 95.00-138.00
LDL-C (mg/dl) 108.08 69.15 0.000
73.34-146.68 48.86-105.65
HDL-C (mg/dl) 38.60 46.44 0.000
34.74-42.46 42.57-50.31
non-HDL-C (mg/dl) 135.10 96.75 0.000
100.36-173.70 69.66-131.58
LDL-C/ HDL-C 2.80 1.45 0.000
1.82-3.50 1.01-2.45
TC/ HDL-C 4.67 3.07 0.000
3.70-5.00 2.46-3.89
Legend: TC- Total cholesterol; Tg- Triglycerides ; LDL-C- Low density
lipoprotein cholesterol; HDL-C- High density lipoprotein cholesterol;
non-HDL-C- Non-high density lipoprotein cholesterol; LDL-C/HDL-C- Ratio
of LDL-C to HDL-C ; TC/HDL-C- Ratio of TC to HDL-C.relative hazards. Also, the study showed that serum
LDL-C, Tg, fasting blood glucose level, BMI or history of
DM was not significantly associated with the risk of MI
[10]. The Framingham heart study also showed that low
level of HDL-C was the major potent lipid risk factor for
the incidence of coronary heart diseases [11]. These
findings are supported by the potential antiatherogenic
properties of HDL-C, including its mediation of reverse
cholesterol transport, in which cholesterol from periph-
eral tissues is returned to the liver for excretion in the
bile [12]. Moreover, HDL-C inhibits Ca2+ induced pro-
coagulant activity on erythrocyte membranes [13]. HDL-
C has also been shown to promote fibrinolysis [14].
Anti-oxidative property of HDL-C could be the other
cardio-protective mechanism [15].
The differences in the median values of each lipid par-
ameter were statistically significant between MI cases
and controls which show that dyslipidemia is one of the
factors responsible for the causation of MI. We found a
good correlation of non-HDL-C with total as well as
LDL cholesterol. This shows that the value of non-HDL
cholesterol also reflects the value of total cholesterol as
well as LDL cholesterol. Non-HDL cholesterol is simply
an estimate of all the atherogenic lipid particles as it
includes LDL cholesterol, intermediate density lipopro-
tein cholesterol as well as very low density lipoprotein
cholesterol. Sensitivity and specificity as well as PPV and
NPV in the study showed that non-HDL-C is more
powerful discriminating factor for MI than LDL-C.
Similarly, results from the ROC curve also confirm that
non-HDL-C is better associated with MI than LDL-C
(Figure 1). We also found that non-HDL-C was signifi-
cantly correlated with all other lipid parameters; how-
ever LDL cholesterol was not significantly associated
with Tg. The superiority of non-HDL-C over LDL-C
may be due to the fact that triglycerides and subse-
quently triglyceride-rich lipoproteins may play an im-
portant role in the causation of MI. 33 cases with MI
have higher Tg value in our study. Many studies have
shown the involvement of Tg and particularly Tg
rich lipoproteins in the pathogenesis of CVD. Tg rich
lipoproteins have been shown to induce endothelial dys-
function, enhance monocyte adhesion [16], enter athero-
sclerotic plaques [17,18] and inhibit reverse cholesterol
transport [19]. The peroxidative products within the
lipid core is also found to involve in plaque fissuring and
lesion disruption [20]. Non-HDL-C has been proposed
Table 3 Diagnostic value of lipid parameters in MI
Parameters Cut-off values Sensitivity (%) Specificity (%) PPV (%) NPV (%)
TC 200 mg/dl 33.33 84.31 68.0 55.84
Tg 150 mg/dl 35.29 82.35 66.67 56.0
LDL-C 100 mg/dl 52.94 70.59 64.29 60
HDL-C 40 mg/dl 58.82 80.39 75.0 66.13
non-HDL-C 130 mg/dl 58.82 72.55 68.18 63.79
LDL-C/HDL-C 2.5 50.98 76.47 68.42 60.94
TC/ HDL-C 5 35.29 84.31 69.23 56.58
Legend: TC- Total cholesterol; Tg- Triglycerides ; LDL-C- Low density lipoprotein cholesterol; HDL-C- High density lipoprotein cholesterol; non-HDL-C- Non-high
density lipoprotein cholesterol; LDL-C/HDL-C- Ratio of LDL-C to HDL-C ; TC/HDL-C- Ratio of TC to HDL-C; PPV- Positive predictive value; NPV- Negative
predictive value.
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patients with high Tg [21]. The findings of Cui et al.; has
also demonstrated non-HDL-C as a better predictor of
CVD mortality than LDL-C during an average follow up
of 19 years in 4462 dyslipidemic patients [4]. The strong
association of lipid parameters with MI in our study is
in agreement with the study of Goliasch et al.; [22].
Among 102 MI patients recruited by the authors, non-
HDL-C was most strongly associated with MI followed
by LDL-C. Similarly, Ridker et al.; showed that non-
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Figure 1 Receiver operating characteristic curve for non-HDL
cholesterol and LDL cholesterol. Area under the curve is greater
for non-HDL cholesterol than for LDL cholesterol which shows that
non- HDL cholesterol is better discriminating factor for myocardial
infarction than LDL cholesterol.lipid parameters than LDL-C as a predictor of future
cardiovascular events in women [23].
Moreover, realizing the atherogenic potential of some
Tg rich lipoproteins, NCEP ATP III has also introduced
non-HDL-C as a secondary target of treatment in
patients with high Tg after achieving LDL-C targets [3].
Non-HDL-C has also several practical advantages in
clinical practice. It can be calculated in the non-fasting
state by subtracting HDL-C from TC. In addition, it can
also be calculated in the setting of hypertriglyceridemia
where LDL-C estimation with Friedwald's formula is less
accurate and is considered inapplicable in cases where
Tg > 400 mg/dl [24].
In our study, we were interested to compare the bad
cholesterols; non-HDL-C versus LDL-C as a discriminat-
ing factor for MI, and we found that non-HDL-C is a
better discriminating parameter than LDL-C for MI. To
measure HDL-C or non-HDL-C we do not need fasting
blood sample whereas to measure LDL-C fasting blood
sample is needed. Thus, the study gives the idea that
both HDL-C and non-HDL-C are better discriminating
parameters than LDL-C for MI and hence we can ana-
lyse random blood for HDL-C and non-HDL-C rather
than waiting for fasting sample to measure LDL-C.
Conclusions
Dyslipidemia is one of the risk factors of MI. HDL-C
and non-HDL-C are better discriminating parameters
than LDL-C for MI. This study gives the idea that we
can simply perform test from random blood sample to
measure HDL-C and non-HDL-C rather than waiting
for fasting sample to measure LDL-C.
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